Drug | Pathway | nNE and PCI (vs NE = 0.3218) |
---|---|---|
Capecitabine | Eicosanoid | 0.3194 (PCI 0.75%) |
Fulvestrant | Bladder cancer signaling (1); estrogen receptor (2); regulation of cellular mechanics by calpain protease (3) | (1) 0.3179 (PCI 1.18%) (2) 0.3137 (PCI 2.50%) (3) 0.3198 (PCI 0.59%) (1–2) 0.3094 (PCI 3.84%) (1–3) 0.3159 (PCI 1.81%) (2–3) 0.3115 (PCI 3.18%) (1–2–3) 0.3071 (PCI 4.56%) |
Gemcitabine | Regulation of cellular mechanics by calpain protease | 0.3198 (PCI 0.59%) |
Methotrexate | FXR/RXR activation | 0.3193 (PCI 0.75%) |
Raloxifene | Estrogen receptor (1); RAR activation (2) | (1) 0.3137 (PCI 2.50%) (2) 0.3170 (PCI 1.47%) (1–2) 0.3098 (PCI 3.70%) |
Tamoxifen | Estrogen receptor (1); factors promoting cardiogenesis in vertebrates (2); human embryonic stem cell pluripotency (3); RAR activation (4) | (1) 0.3137 (PCI 2.50%) (2) 0.3180 (PCI 1.17%) (3) 0.3157 (PCI 1.86%) (4) 0.3170 (PCI 1.47%) (1–2) 0.3092 (PCI 3.88%) (1–3) 0.3071 (PCI 4.56%) (1–4) 0.3098 (PCI 3.70%) (2–3) 0.3098 (PCI 3.70%) (2–4) 0.3129 (PCI 2.74%) (3–4) 0.3103 (PCI 3.56%) (1–2–3) 0.3003 (PCI 6.68%) (2–3–4) 0.3025 (PCI 5.98%) (3–4–1) 0.3051 (PCI 5.18%) (1–2–3–4) 0.2941 (PCI 8.59%) |
Toremifene | FXR/RXR activation (1); pregnenolone biosynthesis (2) | (1) 0.3193 (PCI 0.75%) (2) 0.3192 (PCI 0.79%) (1–2) 0.3165 (PCI 1.61%) |
Vinblastine | Axonal guidance signaling (1); FXR/RXR activation (2) | (1) 0.3216 (PCI 0.05%) (2) 0.3193 (PCI 0.75%) (1–2) 0.3190 (PCI 0.86%) |